Enzyme replacement therapy: current challenges and drug delivery prospects via extracellular vesicles

References

[1] Platt FM.Emptying the stores: lysosomal diseases and therapeutic strategies.Nat Rev Drug Discov2018;17:133-50

[2] Pandey MK,Rani R.Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease.Nature2017;543:108-12

[3] Wraith JE.Lysosomal disorders.Semin Neonatol2002;7:75-83

[4] Solomon M.Lysosomal enzyme replacement therapies: historical development, clinical outcomes, and future perspectives.Adv Drug Deliv Rev2017;118:109-34 PMCID:PMC5828774

[5] Concolino D,Parini R.Enzyme replacement therapy: efficacy and limitations.Ital J Pediatr2018;44:120 PMCID:PMC6238252

[6] Turner CT,Brooks DA.Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.Mol Genet Metab2000;69:277-85

[7] Spada M,Yasuda M.High incidence of later-onset fabry disease revealed by newborn screening.Am J Hum Genet2006;79:31-40 PMCID:PMC1474133

[8] Hsu TR.Fabry disease: Review and experience during newborn screening.Trends Cardiovasc Med2018;28:274-81

[9] Rombach SM,Linthorst GE.Cost-effectiveness of enzyme replacement therapy for Fabry disease.Orphanet J Rare Dis2013;8:29 PMCID:PMC3598841

[10] Germain DP,Falissard B.The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts.Mol Genet Metab Rep2019;19:100454 PMCID:PMC6365982

[11] Kishnani PS,Muldowney L.Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.Mol Genet Metab2016;117:66-83

[12] Le SQ,Clarke D et al.A humoral immune response alters the distribution of enzyme replacement therapy in murine mucopolysaccharidosis type I.Mol Ther Methods Clin Dev2018;8:42-51 PMCID:PMC5684429

[13] Neuwelt E,Abrey L.Strategies to advance translational research into brain barriers.Lancet Neurol2008;7:84-96

[14] Pardridge WM.Biopharmaceutical drug targeting to the brain.J Drug Target2010;18:157-67

[15] Pardridge WM.Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins.Adv Drug Deliv Rev2022;184:114234

[16] Zhu Y,Schuchman EH,Cheng SH.Dexamethasone-mediated up-regulation of the mannose receptor improves the delivery of recombinant glucocerebrosidase to Gaucher macrophages.J Pharmacol Exp Ther2004;308:705-11

[17] Safary A,Mousavi R,Rafi MA.Enzyme replacement therapies: what is the best option?.Bioimpacts2018;8:153-7 PMCID:PMC6128977

[18] Del Grosso A,Angella L.Brain-targeted enzyme-loaded nanoparticles: A breach through the blood-brain barrier for enzyme replacement therapy in Krabbe disease.Sci Adv2019;5:eaax7462 PMCID:PMC6867879

[19] Santi M,Cecchettini A.Protein delivery by peptide-based stealth liposomes: a biomolecular insight into enzyme replacement therapy.Mol Pharm2020;17:4510-21

[20] Abasolo I,Moltó-Abad M.Nanotechnology-based approaches for treating lysosomal storage disorders, a focus on Fabry disease.Wiley Interdiscip Rev Nanomed Nanobiotechnol2021;13:e1684

[21] Cabrera I,Corchero JL.α-Galactosidase-a loaded-nanoliposomes with enhanced enzymatic activity and intracellular penetration.Adv Healthc Mater2016;5:829-40

[22] Ansari NH,Cook JD,Srivastava SK.Delivery of liposome-sequestered hydrophobic proteins to lysosomes of normal and batten disease cells.J Neurosci Res1997;47:341-7

[23] Choi H,Choi C.Exosome-mediated delivery of active glucocerebrosidase to Gaucher model cells.Molecular Genetics and Metabolism2019;126:S38-9

[24] Do MA,Brown A,Lu B.Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles.Sci Rep2019;9:17274 PMCID:PMC6872767

[25] Hugel B,Kunzelmann C.Membrane microparticles: two sides of the coin.Physiology (Bethesda)2005;20:22-7

[26] Ratajczak J,Hayek F,Ratajczak MZ.Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication.Leukemia2006;20:1487-95

[27] Camussi G,Bruno S,Biancone L.Exosomes/microvesicles as a mechanism of cell-to-cell communication.Kidney Int2010;78:838-48

[28] Matsumoto J,Banks WA.The transport mechanism of extracellular vesicles at the blood-brain barrier.Curr Pharm Des2017;23:6206-14

[29] Saint-Pol J,Duban-Deweer S,Karamanos Y.Targeting and crossing the blood-brain barrier with extracellular vesicles.Cells2020;9:851 PMCID:PMC7226770

[30] Seras-Franzoso J,Corchero JL.Extracellular vesicles from recombinant cell factories improve the activity and efficacy of enzymes defective in lysosomal storage disorders.J Extracell Vesicles2021;10:e12058 PMCID:PMC7953474

[31] Haney MJ,Harrison EB,Kabanov AV.TPP1 Delivery To Lysosomes With Extracellular Vesicles And Their Enhanced Brain Distribution In The Animal Model Of Batten Disease.Adv Healthc Mater2019;8:e1801271 PMCID:PMC6584948

[32] Haney MJ,Jin YS.Extracellular vesicles as drug carriers for enzyme replacement therapy to treat CLN₂ batten disease: optimization of drug administration routes.Cells2020;9:1273 PMCID:PMC7290714

[33] European Medicines Agency, Sciences Medicines. Health.Brineura cedipose alpha.

[34] Schulz A,Specchio N.CLN2 Study GroupStudy of intraventricular cerliponase Alfa for CLN₂ Disease.N Engl J Med2018;378:1898-907